Edwards TAVR business contributed the lion’s share of its Q2 revenues at $1.26bn, largely informing its decision to uplift its 2026 revenue growth outlook.

Thermo’s Q2 performance was driven by its laboratory products and biopharma services business with profits around $6.69bn equating to a 12% uptick YoY.

Affinity Technologies has collaborated with Pictor to develop and commercialise new diagnostic tests for asthma and COPD.

GE HealthCare's tool is intended to streamline imaging workflow collaboration between different specialist teams in areas such as oncology.

While not disclosing a specific launch timeframe, with de novo clearance in hand, J&J initially plans to launch Ottava with “select customers”.

Health technology brand Hilo, developed by Aktiia, has launched its Hilo Core blood pressure monitoring system in the US.

Under the deal, Personalis’ minimal residual disease (MRD) test will be integrated into Tempus’ broader oncology portfolio.

Cardinal Health’s acquisitions of Strive Medical and Adapt Health’s diabetes unit are collectively intended to support its at-home care business’s growth strategy.

British Business Bank has previously co-invested in EQT's fund portfolio companies Phagenesis and Cyted Health.

Following TYBR’s B3 GEL’s US launch in January 2026, the company primarily intends to use the funds to expand market access to the hydrogel.

HistoSonics will now initiate a phased commercial rollout of its Edison system across European centres of excellence that specialise in liver tumour treatment.

Neuraptive Therapeutics has secured an exclusive licence from Washington University in St. Louis for a bioresorbable wireless electronic stimulation device designed for peripheral nerve repair.